Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 14;41(3):664–674. doi: 10.1200/JCO.22.01000

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — PFS by independent review in patients with BRAF V600–mutant LGG^a. Kaplan-Meier plots showing PFS in patients with BRAF V600–mutant LGG treated with (A) trametinib monotherapy (n = 13) or (B) dabrafenib + trametinib combination therapy (n = 36), assessed by independent review (RANO 2017). ^aTwo patients with BRAF V600–mutant HGG were enrolled in part C and are included in this predominantly LGG cohort as a diagnosis of HGG did not define any other disease-specific cohort in the trial. HGG, high-grade glioma; LGG, low-grade glioma; PFS, progression-free survival; RANO, Response Assessment in Neuro-Oncology.